ArticleClinical parkinsonism & related disorders2026
Hyperkinetic manifestations in sporadic parkinsonism: An exploratory case series with APOE and NOS3 variants.
Article in Clinical parkinsonism & related disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Hyperkinetic motor features are uncommon in Parkinson's disease and related parkinsonisms and may reflect underlying genetic susceptibility. Methods We describe three sporadic patients with parkinsonism and prominent hyperkinetic manifestations who underwent clinical exome sequencing. To provide preliminary context for these observations, we reviewed genetic data from an additional cohort of 11 patients with sporadic parkinsonism who underwent clinical exome sequencing in our center but did not exhibit early hyperkinetic manifestations Results All patients carried heterozygous variants in genes involved in vascular, inflammatory, and tau related pathways (NOS3 c.774 T > C; APOE c.388 T > C). Clinical phenotypes ranged from late-onset parkinsonism with severe choreic dyskinesias to young-onset dystonic parkinsonism with excellent dopaminergic responsiveness. Dopaminergic dysfunction was supported by functional neuroimaging. Conclusions These cases suggest that APOE and NOS3 variants may act as susceptibility modifiers, predisposing to hyperkinetic phenotypes within the parkinsonian spectrum.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.